|
Propiomazine
drug data and news
Propiomazine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Propiomazine
|
| Brand Names/Synonyms |
CB 1678; CHEMBANK937; HSDB 3275; Largon; Phenoctyl; Propiomazina [Inn-Spanish]; Propiomazine; Propiomazine [Usan:Ban:Inn]; Propiomazinum [Inn-Latin]; Propionylpromethazine; Wy-1359 |
| Indication |
Used to produce sleepiness or drowsiness and to relieve anxiety before or during surgery or certain procedures. Propiomazine is also used with analgesics during labor to produce drowsiness and relieve anxiety. |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, Propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors. |
| Mechanism Of Action |
Propiomazine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Propiomazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Propiomazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with Propiomazine. |
Propiomazine News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
Not Available |
| Drug_Category |
Sedatives and Hypnotics; ATC:N05CM06 |
| Absorption |
Not Available |
| Interactions |
Not Available |
| Toxicity |
Not Available |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
1-[10-(2-dimethylaminopropyl)-10H-phenothiazin-2-yl]propan-1-one |
| Chemical Formula |
C20H24N2OS |
| Molecular Weight |
340.483 g/mol |
| Smiles String |
CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CC(C)N(C)C |
| Melting Point |
Not Available |
| Water Solubility |
0.454 mg/L |
| State |
Solid |
| LogP/Hphobicity |
5.224 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Not Available |
| Half Life |
Not Available |
| Protein Binding [%] |
81% |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
http://www.drugs.com/cons/Propiomazine.html |
| Drug Type |
Approved Drug |
| Accession No |
APRD00339 |
| CAS Registry Number |
362-29-8 |
| KEGG Compound ID |
C07405 |
| PubChem ID |
SID:278825 |
| PharmGKB ID |
PA451137 |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
Not Available
|
|
|
